去年国产疫苗在海外卖了3亿多美元

Core Viewpoint - China's vaccine export value is expected to recover and grow significantly in 2025, reaching $324 million, a year-on-year increase of 52.63% after a modest recovery in 2024 [3][4]. Export Growth - In 2024, China's vaccine export value was $212 million, marking a 4.92% increase, the first positive growth since 2022 [3]. - By 2025, China exported vaccines to 85 global markets, with the top ten markets accounting for 70.04% of the total export value [3]. - Notable growth in exports includes a 130.53% increase to Pakistan, a 119.50% increase to Brazil, and nearly a 30-fold increase to Myanmar [3]. Market Dynamics - Domestic vaccine companies have traditionally focused on established products with lower market risks, leading to increased competition and product homogeneity in the market [3]. - In response to intensified domestic competition, more Chinese vaccine companies are expanding internationally, leveraging opportunities in developing countries along the Belt and Road Initiative [4]. Company Performance - Kangtai Biological (300601.SZ) reported a slight increase in revenue for 2025, with overseas business revenue reaching approximately 98.84 million yuan, a year-on-year increase of 859.40% [4]. - Wantai Biological (603392.SH) is actively expanding its international market presence, achieving significant growth in revenue from its bivalent HPV vaccine [4]. - Watson Biological (300142.SZ) indicated a stabilization in domestic vaccine revenue while experiencing a 35% increase in revenue from exported vaccines [4]. Import Trends - China's vaccine import value has been on the rise since 2014, peaking in 2023, but began to decline in the latter half of 2024 [5]. - The decrease in imported vaccines is attributed to advancements in domestic vaccine production capabilities, with several major products like the nine-valent HPV vaccine and shingles vaccine gaining market share [5].